Replimune Group, Inc.
RP1 (vusolimogene oderparepvec)
advanced melanoma
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for RP1 (vusolimogene oderparepvec) in advanced melanoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Data from the ongoing ARTACUS Phase 2 trial evaluating the potential of RP1 as monotherapy in cutaneous squamous cell carcinoma patients following organ transplant were recently presented during an oral session at the Society for Melanoma R”